Bracco Receives Health Canada Approval for VUEWAY(R) injection (gadopiclenol), Advancing Lower-Dose MRI Contrast Imaging

Approval marks a major milestone in reducing gadolinium exposure while maintaining diagnostic performance, aligning with clinical guidance to use the lowest effective dose MONTREAL, April 17, 2026 ...
Medscape

High-Dose Gadolinium May Be Linked to NSF/NFD in Patients with Renal Failure

June 9, 2006 — The U.S. Food and Drug Administration (FDA) has notified healthcare professionals regarding the potential risk for nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy ...
Monthly Prescribing Reference

Gadopiclenol, a New Macrocyclic Gadolinium-Based Contrast Agent, Gets FDA Approval

Gadopiclenol carries a Boxed Warning associated with an increased risk of nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. The approval of gadopiclenol was based on ...
KXAN

Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY ...

VUEWAY injection is highly stable and shows the highest relaxivity among gadolinium-based contrast agents available for clinical use i VUEWAY injection is approved for use in adult and pediatric ...
Morningstar

FDA Approves VUEWAY® (gadopiclenol) Solution for Injection, Intravenous Use, for Use in Neonates and Infants

Approval expands low-dose MRI contrast options for the youngest patients and reflects a positive benefit–risk profile of VUEWAY® injection from birth through adulthood PRINCETON, N.J., Feb. 23, 2026 ...
Post-Bulletin

Contrast agents help create clear picture in certain types of MRI exams

DEAR MAYO CLINIC: I have had an acoustic neuroma for 10 years. When it was first diagnosed, I had fractionated stereotactic radiosurgery. Since then, I've had 18 MRIs with gadolinium injections. Have ...

MRI warning as study says injection could cause deadly material to form in body

MRI warning as study says injection could cause deadly material to form in body - Researchers recommend that patients not ...

Bracco Receives Health Canada Approval for VUEWAY® injection (gadopiclenol), Advancing Lower-Dose MRI Contrast Imaging

Bracco Imaging, a global leader in diagnostic imaging, today announced that Health Canada approved VUEWAY® injection (gadopiclenol), a macrocyclic gadolinium-based contrast agent (GBCA), for use in ...